FDA Eases Path for Restless Legs Nerve Stimulator
Published Date: 6/26/2026
Rule
Summary
The FDA has officially placed the external lower leg nerve stimulator for Restless Legs Syndrome into a safer, easier-to-get category called Class II. This change helps patients get access to this helpful device faster while keeping safety in check. The new rules took effect on June 26, 2026, and could lower costs by cutting some red tape for makers and users alike.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Device moved to Class II — faster access
The FDA has classified the external lower extremity nerve stimulator for Restless Legs Syndrome as Class II (special controls). The order is effective June 26, 2026 (classification was applicable April 17, 2023), and FDA says this Class II classification will provide reasonable assurance of safety and enhance patients' access by reducing regulatory burdens.
De Novo ruling creates predicate for future devices
FDA states that when it classifies a device into Class I or II via the De Novo process, that device can serve as a predicate for future devices. As a result, other device sponsors can use the less-burdensome 510(k) process instead of submitting a De Novo request or a premarket approval application.
New special controls set testing and labeling rules
FDA requires special controls for this device that include non-clinical performance testing (e.g., electrical stimulation parameters such as waveforms, maximum output voltage and current at 500 Ω, 2k Ω, and 10k Ω loads; pulse duration; frequency), electrode performance (adhesive integrity, shelf life, reusability), biocompatibility testing, electrical/thermal/mechanical safety and electromagnetic compatibility testing, software verification and validation, and physician and patient labeling (including recommended treatment regimens, typical sensations, methods to set stimulation intensity, electrode shelf life/reuse, and maintenance instructions).
Device is prescription-only
The external lower extremity nerve stimulator is identified as a prescription device and is for prescription use only. That means you must obtain a prescription from a health care provider to get this device.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19704, Robotically-Assisted Surgical Devices-Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just dropped a draft guide for companies making robot-assisted surgical devices, showing how to get their products approved before selling. If you’re in the biz, now’s the time to check it out and send your feedback by November 24, 2026. This guide aims to make the approval process clearer and smoother, potentially saving time and money down the road.
2026-19655, Jeffrey Thies: Final Debarment Order
Jeffrey Thies is banned for 10 years from importing any drugs into the U.S. because he was convicted of trafficking fake drugs. He didn’t respond to the FDA’s notice, so the ban started on September 25, 2026. He can apply to end the ban anytime, but until then, no drug imports for him!
Previous / Next Documents
Previous: 2026-12903, Medical Devices; General and Plastic Surgery Devices; Classification of the Breast Implant Suction Retrieval System
The FDA has officially placed the breast implant suction retrieval system into Class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps make the device safer and easier to get to patients without unnecessary delays. The new classification took effect on June 26, 2026, and could speed up innovation while keeping costs in check for makers and users.
Next: 2026-12905, Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep System
The FDA has officially placed the infant supine sleep system into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps make sure the device is safe and effective while making it easier for companies to bring these helpful baby sleep products to market. The new classification took effect on June 26, 2026, but has been in place since March 30, 2023, so manufacturers and parents can breathe easy!